Modra Pharmaceuticals Announces U.S. Patent Issuance for ModraDoc006/r

2023-03-16

临床2期临床结果临床3期

AMSTERDAM--(BUSINESS WIRE)-- Modra Pharmaceuticals (“Modra”) today announced that the U.S. Patent and Trademark Office (USPTO) has issued to Modra U.S. Patent No. 11,571,408, covering the use of its oral taxane therapeutic ModraDoc006/r. ModraDoc006/r is an oral tablet formulation of docetaxel co-administered with ritonavir, a boosting agent that enhances bioavailability. ModraDoc006/r has been designed to be an effective anti-cancer therapeutic which can be taken at home and which eliminates or reduces serious, treatment-limiting side effects. The patent provides protection for ModraDoc006/r until 2039. “In clinical testing to date, ModraDoc006/r has demonstrated an attractive efficacy pro avoiding levels of neutropenia, anemia, alopecia and peripheral neuropathy that are common with IV administration of docetaxel chemotherapy,” said Colin Freund, CEO of Modra Pharmaceuticals. “The grant of this patent by the USPTO, which significantly extends our patent coverage until 2039, is a validation of our differentiated approach and underscores our commitment to bringing safer and more convenient treatment options to cancer patients.” The patent covers the use of Modra’s compound, ModraDoc006, an oral formulation of docetaxel, at doses which control side effects by preventing elevated peak plasma levels of docetaxel, while maintaining an effective plasma level of docetaxel to eradicate tumor cells. High peak plasma levels (and consequent higher toxicities) are a consequence of the IV administration of docetaxel, which historically has been widely used as a chemotherapy for many types of solid tumors. The company announced the results from its Phase 2b trial with ModraDoc006/r in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) in mid-2022. ModraDoc006/r demonstrated a significantly improved safety pro to standard-of-care IV chemotherapy docetaxel at 75 mg/m2 Q3W. Based on the results, Modra is planning for a Phase 3 pivotal trial in mCRPC patients. About Modra Pharmaceuticals Modra Pharmaceuticals aims to transform taxane therapy by developing therapies that are effective, less toxic and can be taken at home. The Company’s goal is to dramatically improve the therapeutic outcomes and everyday lives of the hundreds of thousands of cancer patients undergoing taxane therapy worldwide. Modra’s lead program is ModraDoc006/r, an oral docetaxel-based therapy which has completed a Phase 2b clinical study in prostate cancer, resulting in positive date further supporting the delivery, bioavailability and tolerability of its novel approach. View source version on businesswire.com: Contacts Colin Freund CEO, Modra Pharmaceuticals colin.freund@modrapharmaceuticals.com Tel: +1 609 933 8008 Trophic Communications Valeria Fisher or Desmond James modra@trophic.eu Tel: +49 (0) 175 804 1816 or +49 (0) 1516 7859086 Source: Modra Pharmaceuticals View this news release online at:

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构